{"id":"https://openalex.org/W7117115292","doi":"https://doi.org/10.3389/fphar.2026.1927878","title":"Arctiin attenuates the development of psoriasis-like dermatitis and modulates EGFR-associated ERK signaling","display_name":"Arctiin attenuates the development of psoriasis-like dermatitis and modulates EGFR-associated ERK signaling","publication_year":2026,"publication_date":"2026-11-11","ids":{"openalex":"https://openalex.org/W7117115292","doi":"https://doi.org/10.3389/fphar.2026.1927878"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.1927878","doi":"https://doi.org/10.3389/fphar.2026.1927878","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1927878","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1927878/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1927878/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5121173767","display_name":"Mengyao Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I34077901","display_name":"Juntendo University","ror":"https://ror.org/01692sz90","country_code":"JP","type":"education","lineage":["https://openalex.org/I34077901"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Mengyao Yang","raw_affiliation_strings":["Juntendo University, 2 Chome-1-1 Hongo, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juntendo University, 2 Chome-1-1 Hongo, Tokyo, Japan","institution_ids":["https://openalex.org/I34077901"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5130395554","display_name":"Ge Peng","orcid":"https://orcid.org/0000-0002-3278-2604","observed_orcids":["https://orcid.org/0000-0002-3278-2604"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Ge Peng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021907422","display_name":"Quan Xi Sun","orcid":"https://orcid.org/0000-0002-7228-9363","observed_orcids":["https://orcid.org/0000-0002-7228-9363"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Quan Sun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104749955","display_name":"Alafate Abudouwanli","orcid":"https://orcid.org/0009-0006-9427-8258","observed_orcids":["https://orcid.org/0009-0006-9427-8258"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alafate Abudouwanli","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5121178026","display_name":"Wanchen Zhao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wanchen Zhao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103055472","display_name":"Yi Lin Tan","orcid":"https://orcid.org/0000-0003-2050-3118","observed_orcids":["https://orcid.org/0000-0003-2050-3118"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yi Tan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5121180656","display_name":"Shan Wang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shan Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101674678","display_name":"Hideoki Ogawa","orcid":"https://orcid.org/0000-0003-4268-8790","observed_orcids":["https://orcid.org/0000-0003-4268-8790"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hideoki Ogawa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088986458","display_name":"Ko Okumura","orcid":"https://orcid.org/0000-0003-3238-6422","observed_orcids":["https://orcid.org/0000-0003-3238-6422"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ko Okumura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5121161579","display_name":"Long Geng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Long Geng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5065203157","display_name":"Fran\u00e7ois Niyonsaba","orcid":"https://orcid.org/0000-0002-0588-8315","observed_orcids":["https://orcid.org/0000-0002-0588-8315"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fran\u00e7ois Niyonsaba","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5130395554"],"corresponding_institution_ids":[],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13026","display_name":"Natural Compounds in Disease Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2707","display_name":"Complementary and alternative medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/arctiin","display_name":"arctiin","score":0.9950000047683716},{"id":"https://openalex.org/keywords/psoriasis","display_name":"psoriasis","score":0.8629999756813049},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.7080000042915344},{"id":"https://openalex.org/keywords/fructus-arctii","display_name":"Fructus Arctii","score":0.9449999928474426},{"id":"https://openalex.org/keywords/arctium-lappa","display_name":"Arctium lappa","score":0.9950000047683716},{"id":"https://openalex.org/keywords/imiquimod-induced-psoriasis-like-dermatitis","display_name":"imiquimod-induced psoriasis-like dermatitis","score":0.8600000143051147},{"id":"https://openalex.org/keywords/keratinocyte-hyperproliferation","display_name":"keratinocyte hyperproliferation","score":0.8790000081062317},{"id":"https://openalex.org/keywords/pro-inflammatory-cytokines","display_name":"inflammatory cytokines","score":0.7390000224113464},{"id":"https://openalex.org/keywords/epidermal-hyperplasia","display_name":"epidermal hyperplasia","score":0.7940000295639038},{"id":"https://openalex.org/keywords/anti-inflammatory-natural-compounds","display_name":"anti-inflammatory natural compounds","score":0.4860000014305115}],"concepts":[{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.7448999881744385},{"id":"https://openalex.org/C164027704","wikidata":"https://www.wikidata.org/wiki/Q3491837","display_name":"Proinflammatory cytokine","level":3,"score":0.6172000169754028},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5995000004768372},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.5751000046730042},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5295000076293945},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5019999742507935},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.4909000098705292},{"id":"https://openalex.org/C83415579","wikidata":"https://www.wikidata.org/wiki/Q161973","display_name":"Arc (geometry)","level":2,"score":0.483599990606308},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.41940000653266907},{"id":"https://openalex.org/C13373296","wikidata":"https://www.wikidata.org/wiki/Q421866","display_name":"Chemokine","level":3,"score":0.37700000405311584},{"id":"https://openalex.org/C2777074287","wikidata":"https://www.wikidata.org/wiki/Q1473931","display_name":"Keratinocyte","level":3,"score":0.3700000047683716},{"id":"https://openalex.org/C136449434","wikidata":"https://www.wikidata.org/wiki/Q428253","display_name":"Innate immune system","level":3,"score":0.33719998598098755},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.3163999915122986},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.3077000081539154},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.2937000095844269},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.2806999981403351},{"id":"https://openalex.org/C85265743","wikidata":"https://www.wikidata.org/wiki/Q885458","display_name":"Blot","level":3,"score":0.2759999930858612},{"id":"https://openalex.org/C118995209","wikidata":"https://www.wikidata.org/wiki/Q5636366","display_name":"HaCaT","level":3,"score":0.2653999924659729},{"id":"https://openalex.org/C150555746","wikidata":"https://www.wikidata.org/wiki/Q210973","display_name":"Cell signaling","level":3,"score":0.26440000534057617},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.25519999861717224},{"id":"https://openalex.org/C2779703632","wikidata":"https://www.wikidata.org/wiki/Q581996","display_name":"Anti-inflammatory","level":2,"score":0.2526000142097473},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.251800000667572}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3389/fphar.2026.1927878","doi":"https://doi.org/10.3389/fphar.2026.1927878","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1927878","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1927878/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"doi:10.2139/ssrn.5929508","doi":"https://doi.org/10.2139/ssrn.5929508","is_oa":true,"landing_page_url":"https://doi.org/10.2139/ssrn.5929508","pdf_url":null,"source":{"id":"https://openalex.org/S4210172589","display_name":"SSRN Electronic Journal","issn_l":"1556-5068","issn":["1556-5068"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1318003438","host_organization_name":"RELX Group (Netherlands)","host_organization_lineage":["https://openalex.org/I1318003438"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.1927878","doi":"https://doi.org/10.3389/fphar.2026.1927878","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1927878","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1927878/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7117115292.pdf","grobid_xml":"https://content.openalex.org/works/W7117115292.grobid-xml"},"referenced_works_count":40,"referenced_works":["https://openalex.org/W978308701","https://openalex.org/W1963531920","https://openalex.org/W1965457590","https://openalex.org/W1975875310","https://openalex.org/W1981814215","https://openalex.org/W2012034410","https://openalex.org/W2033495141","https://openalex.org/W2038085058","https://openalex.org/W2043509228","https://openalex.org/W2070911023","https://openalex.org/W2113364934","https://openalex.org/W2166817851","https://openalex.org/W2314166032","https://openalex.org/W2593436234","https://openalex.org/W2971816091","https://openalex.org/W3025501607","https://openalex.org/W3120428759","https://openalex.org/W3157784408","https://openalex.org/W3162903830","https://openalex.org/W3184729641","https://openalex.org/W3185901359","https://openalex.org/W3197589315","https://openalex.org/W3205956676","https://openalex.org/W3212070111","https://openalex.org/W4207039412","https://openalex.org/W4211202219","https://openalex.org/W4223477706","https://openalex.org/W4225081109","https://openalex.org/W4283798043","https://openalex.org/W4320038739","https://openalex.org/W4322505937","https://openalex.org/W4388615901","https://openalex.org/W4389030365","https://openalex.org/W4389097234","https://openalex.org/W4389461583","https://openalex.org/W4393214822","https://openalex.org/W4404008096","https://openalex.org/W4408548930","https://openalex.org/W4409148041","https://openalex.org/W4414776399"],"related_works":["https://openalex.org/W4400826219","https://openalex.org/W4416723040","https://openalex.org/W4416586107","https://openalex.org/W3135006969","https://openalex.org/W7017505971","https://openalex.org/W4386209452","https://openalex.org/W4379928505","https://openalex.org/W3035373797","https://openalex.org/W4413309130","https://openalex.org/W4404637917"],"abstract_inverted_index":{"Background":[0],"Psoriasis":[1],"is":[2,304],"a":[3,33,121,320],"chronic":[4],"immune-mediated":[5],"inflammatory":[6,51,110,144,177,229,274],"skin":[7,164,210],"disease":[8,27],"characterized":[9],"by":[10],"keratinocyte":[11],"hyperproliferation,":[12],"immune":[13,103,169],"cell":[14,104,170],"infiltration,":[15,105,171],"and":[16,46,61,79,109,145,152,172,175,211,231,238,289,303],"increased":[17,202],"dermal":[18,106,173],"angiogenesis.":[19],"Although":[20],"current":[21],"therapies":[22],"provide":[23],"symptomatic":[24],"relief,":[25],"long-term":[26],"control":[28],"remains":[29],"challenging.":[30],"Arctiin":[31],"(ARC),":[32],"major":[34],"lignan":[35],"glycoside":[36],"of":[37,56,73,88,124,161,204,215,227,235,247,255,266,271,300,309],"Arctii":[38],"Fructus":[39],"from":[40],"Arctium":[41],"lappa":[42],"L.,":[43],"exerts":[44],"anti-inflammatory":[45],"immunomodulatory":[47],"effects":[48,55,72,87,265],"on":[49,58,249,268],"several":[50,192,272],"diseases.":[52],"However,":[53],"the":[54,62,71,81,159,213,225,233,243,253,263,269,278,298,307],"ARC":[57,74,90,156,223,248,267,281,296,317],"psoriasis-like":[59,97,163,301],"inflammation":[60,302],"signaling":[63,82,134,146,194,217],"mechanisms":[64],"involved":[65],"remain":[66],"unclear.":[67],"Purpose":[68],"To":[69],"investigate":[70],"in":[75,94,208,218,292],"psoriasis-related":[76,273],"experimental":[77,137],"models":[78],"elucidate":[80],"pathways":[83],"involved.":[84],"Methods":[85],"The":[86,180],"oral":[89],"administration":[91,157,282],"were":[92,113,148],"evaluated":[93,149],"an":[95],"imiquimod-induced":[96,162],"dermatitis":[98],"model.":[99],"Clinical":[100],"severity,":[101],"histopathology,":[102],"vascular":[107],"changes,":[108],"gene":[111],"expression":[112,203,226,270],"assessed.":[114],"An":[115],"exploratory":[116,181],"network":[117,182],"analysis,":[118],"together":[119],"with":[120,277,285,306],"transcriptomic":[122,199],"analysis":[123,183],"publicly":[125],"available":[126],"human":[127,141,197],"psoriasis":[128,198],"datasets,":[129],"was":[130,283],"used":[131],"to":[132],"prioritize":[133],"nodes":[135],"for":[136,324],"investigation.":[138],"In":[139,221],"primary":[140],"keratinocytes,":[142,222],"ARC-mediated":[143],"responses":[147],"using":[150],"RT\u2012qPCR":[151],"immunoblotting.":[153],"Results":[154],"Oral":[155],"attenuated":[158,262],"development":[160,299],"lesions;":[165],"reduced":[166,224,286],"epidermal":[167,186,219],"hyperplasia,":[168],"angiogenesis;":[174],"downregulated":[176],"mediator":[178],"expression.":[179],"recurrently":[184],"prioritized":[185],"growth":[187],"factor":[188],"receptor":[189],"(EGFR)":[190],"among":[191],"candidate":[193,322],"nodes,":[195],"whereas":[196,252],"data":[200],"revealed":[201],"multiple":[205],"EGFR":[206,240,259],"ligands":[207],"lesional":[209],"supported":[212],"relevance":[214],"EGFR-associated":[216,310],"keratinocytes.":[220],"psoriasis-associated":[228],"mediators":[230],"suppressed":[232],"phosphorylation":[234,257,291],"EGFR,":[236,287],"ERK,":[237,288],"JNK.":[239],"knockdown":[241,260],"abolished":[242],"additional":[244],"suppressive":[245],"effect":[246],"ERK":[250,311],"phosphorylation,":[251],"suppression":[254],"JNK":[256,290],"persisted.":[258],"also":[261],"inhibitory":[264],"mediators.":[275],"Consistent":[276],"cellular":[279],"findings,":[280],"associated":[284,305],"imiquimod-treated":[293],"skin.":[294],"Conclusion":[295],"attenuates":[297],"modulation":[308],"signaling.":[312],"These":[313],"findings":[314],"suggest":[315],"that":[316],"may":[318],"represent":[319],"potential":[321],"treatment":[323],"psoriasis.":[325]},"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2025-12-24T00:00:00"}